New concept drug hunts down late-stage prostate cancer
2021-07-11
(Press-News.org) A new class of drug successfully targets treatment-resistant prostate cancers and prolongs the life of patients. The treatment delivers beta radiation directly to tumour cells, is well tolerated by patients and keeps them alive for longer than standard care, found a phase 3 trial to be presented at the European Association of Urology congress, EAU21, today.
Despite progress in medicine in recent years, metastatic castration-resistant prostate cancer remains untreatable and fatal. The new treatment, known as Lu-PSMA-617, takes a new approach, targeting a molecule called PSMA, which is known to be increased on the surfaces of the tumour cells, destroying them and their surrounding microenvironment.
Professor Johann de Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, and Professor Ken Herrmann, Director of the Clinic for Nuclear Medicine at University Hospital Essen, Germany, and an international team of researchers set out to see whether Lu-PSMA-617 was more effective than standard care and recruited 831 patients with metastatic castration-resistant prostate cancer between June 2018 and October 2019. Patients were randomly assigned to receive the treatment plus standard care or standard care alone.
They report that the treatment significantly improved survival of patients by an average of four months, compared with standard treatment. Median survival time was 15.3 for the treatment group and 11.3 months for those receiving standard care. Progression-free survival, or the time before a patient's tumour became worse, was also longer with the treatment: a median of 8.7 months compared with 3.4 months for those with standard care.
The trial also compared side effects, finding that health-related quality of life was not negatively affected, and the team concludes that it is an effective and safe medicine that can improve standard of care for patients with this advanced prostate cancer.
Professor Ken Herrmann says: "This is a completely new therapeutic concept; a precision medicine that delivers radiation directly to a high incidence tumour. The treatment was well tolerated by patients and they had an average of four months' longer survival with good quality of life. Lu-PSMA-617 can improve the lives of many men with advanced prostate cancer and their families."
Professor Johann de Bono says: "Our findings show that this potent radioactive medicine can deliver radiation precisely to cancer cells and destroy them, extending patients' lives. I hope men whose tumours have high levels of PSMA can soon benefit from this highly innovative treatment. Currently, the treatment is being appraised by the National Institute for Health and Care Excellence (NICE) for use in the NHS in England and Wales."
"Using the PSMA molecule to directly target prostate cancer cells is the beginning of a new era of precision medicine in urology diagnostics as well as therapy", says Professor Peter Albers, Head of the Department of Urology, Dusseldorf University, and Chair of the Scientific Office of the EAU. "LU-PSMA-617 was tested in so-called end-stage disease and still showed superiority and this paves the way for studies to treat patients in earlier stages. We have seen similar success in the diagnostic setting, using this molecule to improve the way we stage tumours. This targeted approach will revolutionise the way we approach the treatment of men with prostate cancer in the future."
INFORMATION:
ELSE PRESS RELEASES FROM THIS DATE:
2021-07-11
Using an existing drug for late-stage kidney cancer at an earlier stage of the disease could reduce the risk of cancer recurring by a third, according to new research.
The findings from the Phase III trial are presented today at the European Association of Urology congress (EAU21).
There is a high risk of kidney cancer returning, following surgery to remove tumours, but there is currently no treatment to help prevent this.
The KEYNOTE study involved just under 1000 patients with kidney cancer who had undergone surgery. Half of them were given the immunotherapy drug pembrolizumab, or pembro, and the other half a placebo.
Pembro is used to treat a number of cancers, including late-stage kidney cancer, where the disease has spread to ...
2021-07-11
Researchers in Belgium report on the case of a 90-year-old woman who was simultaneously infected with two different variants of concern (VOCs) of COVID-19, in a Case Report being presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) held online this year.
On March 3 2021, the woman, whose medical history was unremarkable, was admitted to the OLV Hospital in the Belgian city of Aalst after a spate of falls. She tested positive for COVID-19 on the same day. She lived alone and received nursing care at home, and had not been vaccinated against COVID-19.
Initially, there were no ...
2021-07-11
New research being presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), held online this year, reveals raw dog food to be a major source of antibiotic-resistant bacteria, making it an international public health risk.
With some of the multidrug-resistant bacteria in raw dog food identical to those found in hospital patients in several different European countries, the researchers say the trend for feeding dogs raw food may be fuelling the spread of antibiotic resistant-bacteria.
Drug-resistant infections kill an estimated 700,000 people a year globally and, with the figure projected to rise to 10 million ...
2021-07-11
The dangerous mcr-1 gene, which provides resistance to the last-resort antibiotic colistin, has been found in four healthy humans and two pet dogs. In two cases, both dog and owner were harbouring the gene, according to new research being presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) held online this year.
Since first being reported in China in 2015, the mcr-1 gene has been found in various people and animals around the world. It confers resistance to colistin, an antibiotic of last resort used to treat infections from some bacteria resistant to all other antibiotics. The nightmare scenario that could emerge is mcr-1 combining with already drug-resistant bacteria ...
2021-07-10
Nashville, Tenn. (3:24 p.m. EDT--July 10, 2021)--Approximately 12 percent of patients who underwent shoulder stabilization surgery experience arthritis in the shoulder joint within a seven-year period, according to research presented today at the American Orthopedic Society for Sports Medicine-Arthroscopy Association of North America Combined 2021 Annual Meeting.
"While arthroscopic stabilization for posterior glenohumeral instability has shown excellent success preventing recurrent instability and allowing return to sport, eventual progression to glenohumeral arthritis ...
2021-07-10
Nashville, Tenn. (July 10 2021--2:25 EDT)--Patients undergoing hip arthroscopy with high-grade cartilage damage do not see as positive results compared with patients with lower grade cartilage damage, according to research reported today at the American Orthopedic Society of Sports Medicine- Arthroscopy Association of North America Combined 2021 Annual Meeting.
The research was presented by Dominic Carreira, MD, of Peachtree Orthopedics in Atlanta, Ga. Dr. Carreira and his colleagues sought to determine what the impact of acetabular cartilage damage on outcomes following primary repair of acetabular labral tears.
When articular cartilage is damaged, joint ...
2021-07-10
Nashville, Tenn. (1:35 p.m. EDT--July 10, 2021) -- Use of a biodegradable balloon spacer during massive rotator cuff tear surgery produced similar outcomes when compared to partial rotator cuff repair for patients with massive rotator cuff tears (MRCTs) at 24-month follow up, with potential for early improvement, according to research presented today at the American Orthopedic Society of Sports Medicine - Arthroscopy Association of North America Combined 2021 Annual Meeting.
Despite various treatment options, the successful management of irreparable, MRCTs remains challenging. Implantation of a biodegradable subacromial balloon spacer has gained considerable interest for the treatment of MCRTs due to its potential to recenter the humeral ...
2021-07-10
"Topological defects" are formed when the symmetry of a magnetic material is disrupted. Domain walls (DWs) are a type of topological defect that separates regions of different magnetic orientations. A widely studied phenomenon, the manipulation of these defects has potential applications in high-performance memory storage devices, energy processing devices, and quantum computing.
Recently, the possibility of other topological defects embedded in or combined with DWs has gained attention for their potential applications in different fields of physics. Some examples of these "defects within defects" ...
2021-07-10
Supplementing testosterone significantly reduces heart attacks and strokes in men with unnaturally low levels of the hormone, according to new research presented at the European Association of Urology congress today.
The ten-year study involved over 800 men from Germany and Qatar with testosterone deficiency, whose family history, blood pressure, cholesterol levels, diabetes or weight put them at high risk of heart attack or stroke.
Only men with testosterone levels below normal, who also displayed symptoms of low testosterone, such as low mood, decreased appetite, depression, erectile dysfunction, loss of libido or weight gain, were included in the research.
Just ...
2021-07-10
Outpatient antibiotic prescribing fell by almost 4% a year between 2011 and 2018, according to a study of prescribing patterns in the largest integrated health care system in the USA, being presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) held online this year.
Veterans Affairs (VA) facilities play a large role in the provision of outpatient care across the USA, providing care to over 9 million Veterans at more than 1,200 outpatient clinics.
The researchers speculate that the downward trend may be related to the antibiotic stewardship programmes widely implemented across the Veterans ...
LAST 30 PRESS RELEASES:
[Press-News.org] New concept drug hunts down late-stage prostate cancer
